News | June 01, 2021
Marksans Pharma Q4 FY21 profit up 86%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
Relonchem receives marketing authorization for Moxonidine tablets
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The Subsidiary has received one inspectional observation in Form 483
Alkem Medtech to acquire 100% stake of Bombay Ortho
USFDA inspection at Emcure Pharmaceuticals API facility
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Subscribe To Our Newsletter & Stay Updated
